SCHEMBL982140

SCHEMBL982140

CCc1ccc[c]c1-c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.35
GABRB2 P47870 2/20 0.35
TP53 P04637 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP2D6 P10635 1/20 0.33
MGLL Q99685 1/20 0.33
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
DPP4 P27487 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KMT2A Q03164 1/20 0.32
SLC22A2 O15244 1/20 0.31
SLC22A1 O15245 1/20 0.31
SLC22A3 O75751 1/20 0.31
SLC6A4 P31645 1/20 0.31
CLCN2 P51788 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2722296 0.85 EGFR (0.38) GABRA1GABRB2TP53MGLL
SCHEMBL983255 0.85 SREBF2 (0.33) L3MBTL1MAPTSMN1; SMN2PDCD1CD274
SCHEMBL982519 0.82 LIPG (0.39) CYP2D6
SCHEMBL15049712 0.80 BCL2 (0.44) GABRA1GABRB2TP53MGLL
SCHEMBL981932 0.80 LIPG (0.45) TP53MAPTKMT2A
SCHEMBL6928439 0.80 CYP2D6 (0.41) GABRA1GABRB2L3MBTL1MAPTSMN1; SMN2
SCHEMBL28033647 0.80 DPP4 (0.50) SMN1; SMN2CYP2D6DPP4
SCHEMBL7703138 0.80 ALDH1A1 (0.34) DPP4
SCHEMBL7698397 0.80 PDCD1 (0.44) L3MBTL1MAPTPDCD1CD274DPP4
SCHEMBL1664569 0.79 GABRA1 (0.41) GABRA1GABRB2PDCD1CD274KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275406-B1 PROCESS FOR PRODUCING ISOCYANATE ASAHI CHEMICAL IND (JP) 2018-11-28 EP disclosed
US-9233918-B2 Isocyanate production process ASAHI KASEI CHEMICALS CORPORATION (JP) 2016-01-12 US disclosed
CN-102026965-B Method for producing isocyanate ASAHI KASEI CHEMICALS CORP 2014-02-26 CN disclosed
EP-2513125-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2012-10-24 EP disclosed
EP-2493906-A1 HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2012-09-05 EP disclosed
US-7977504-B2 Process for producing isocyanates and aromatic hydroxy compounds ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-07-12 US disclosed
WO-2011073149-A1 METAL COMPLEXES COMPRISING DIAZABENZIMIDAZOL CARBENE-LIGANDS AND THE USE THEREOF IN OLEDS BASF SE (DE) 2011-06-23 WO disclosed
WO-2011051404-A1 HETEROLEPTIC CARBENE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2011-05-05 WO disclosed
US-20110092731-A1 ISOCYANATE PRODUCTION PROCESS ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-04-21 US disclosed
EP-2275406-A1 PROCESS FOR PRODUCING ISOCYANATE Asahi Kasei Chemicals Corporation (JP) 2011-01-19 EP disclosed
US-20100274047-A1 PROCESS FOR PRODUCING OF ISOCYANATES AND AROMATIC HYDROXY COMPOUNDS ASAHI KASEI CHEMICALS CORPORATION (JP) 2010-10-28 US disclosed
EP-0977724-A1 PROCESS FOR CHIRAL ENRICHMENT OF OPTICALLY ACTIVE CARBOXYLIC ACIDS, OR SALTS OR ESTERS THEREOF ALBEMARLE CORPORATION (US) 2000-02-09 EP disclosed
US-5936118-A Process for chiral enrichment of optically active carboxylic acids or salts or esters thereof ALBEMARLE CORPORATION (US) 1999-08-10 US disclosed
EP-0925267-A1 RACEMIZATION PROCESS FOR OPTICALLY ACTIVE CARBOXYLIC ACIDS OR SALTS OR ESTERS THEREOF ALBEMARLE CORPORATION (US) 1999-06-30 EP disclosed
US-5847202-A Racemization process for optically active carboxylic acids or salts or esters thereof ALBEMARLE CORPORATION (US) 1998-12-08 US disclosed
WO-1998045240-A1 PROCESS FOR CHIRAL ENRICHMENT OF OPTICALLY ACTIVE CARBOXYLIC ACIDS, OR SALTS OR ESTERS THEREOF ALBEMARLE CORPORATION (US) 1998-10-15 WO disclosed
WO-1997047572-A1 RACEMIZATION PROCESS FOR OPTICALLY ACTIVE CARBOXYLIC ACIDS OR SALTS OR ESTERS THEREOF ALBEMARLE CORPORATION (US) 1997-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092731-A1 ISOCYANATE PRODUCTION PROCESS CPS1, PHGDH, APEH GABRA1 4305/4885GABRB2 3761/4885TP53 1912/4885
US-20100274047-A1 PROCESS FOR PRODUCING OF ISOCYANATES AND AROMATIC HYDROXY COMPOUNDS PAH, APEH, HPD GABRA1 2713/4885GABRB2 3296/4885TP53 2384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.